Effectiveness of @entity3479 in acute XXXX : outcome relates to appropriateness.

@entity1 @entity64 @entity548 @entity16 @entity3479 @entity204 @entity385
OBJECTIVE: To examine whether the demonstrated efficacy of @entity3479 ( @entity3479 ) for acute @entity385 can be effective in a community setting. METHODS: Sixty-eight consecutive @entity1 with acute @entity385 treated with IV @entity3479 within 3 hours of symptom onset by attending general neurologists in a busy teaching hospital. Outcome measures at 3 months were the National Institute of Health @entity64 Scale (NIHSS), functional outcome (independence [modified Rankin score 0-2], dependence [modified Rankin score 3-5], and @entity204 ), and symptomatic @entity548 . Appropriately treated @entity1 were defined by adherence to the National Institute of @entity16 and @entity64 (NINDS) guidelines. Effectiveness is expressed as the absolute risk reduction in which the baseline risk is assumed to be similar to that of the NINDS control group. RESULTS: Of 68 consecutively treated @entity1 (with a mean baseline NIHSS score of 15 +/- 6), 26 (38%) made a full recovery and 39 (57%) made an independent recovery. The 11 @entity1 who violated protocol had a lower probability of independence (p < 0.02) and full neurologic recovery (p < 0.02) and a higher probability of symptomatic @entity548 (p < 0.05) and @entity204 (p < 0.01) compared with those of 57 @entity1 treated according to NINDS guidelines. CONCLUSIONS: The use of @entity3479 for @entity64 in this community is effective with a number needed to treat of six. The risk of symptomatic @entity548 is similar to that noted in randomized trials. Treating @entity1 who violate protocol results in excess risk with no observable benefit.
